Bone Long Term Debt vs Total Stockholder Equity Analysis

BBLGW Stock  USD 60.50  0.00  0.00%   
Bone Biologics financial indicator trend analysis is way more than just evaluating Bone Biologics Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bone Biologics Corp is a good investment. Please check the relationship between Bone Biologics Long Term Debt and its Total Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Long Term Debt vs Total Stockholder Equity

Long Term Debt vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bone Biologics Corp Long Term Debt account and Total Stockholder Equity. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Bone Biologics' Long Term Debt and Total Stockholder Equity is 0.12. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Bone Biologics Corp, assuming nothing else is changed. The correlation between historical values of Bone Biologics' Long Term Debt and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Bone Biologics Corp are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Long Term Debt i.e., Bone Biologics' Long Term Debt and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.12
Relationship DirectionPositive 
Relationship StrengthInsignificant

Long Term Debt

Long-term debt is a debt that Bone Biologics Corp has held for over one year. Long-term debt appears on Bone Biologics Corp balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Bone Biologics Corp balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.
Most indicators from Bone Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
At this time, Bone Biologics' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to climb to 0.20 in 2024, whereas Selling General Administrative is likely to drop slightly above 2 M in 2024.
 2022 2023 2024 (projected)
Tax Provision3.2K3.7K2.1K
Interest Expense2.2M2.0M1.5M

Bone Biologics fundamental ratios Correlations

-0.39-0.21-0.36-0.42-0.39-0.49-0.340.240.67-0.63-0.51-0.56-0.74-0.39-0.37-0.2-0.61-0.080.7-0.52-0.44-0.230.03-0.370.21
-0.39-0.650.990.761.00.65-0.110.62-0.450.59-0.25-0.070.550.67-0.31-0.270.35-0.57-0.330.380.440.90.610.49-0.58
-0.21-0.65-0.68-0.34-0.66-0.180.56-0.99-0.02-0.120.890.730.08-0.430.820.340.210.81-0.210.01-0.15-0.8-0.78-0.280.7
-0.360.99-0.680.780.990.66-0.120.64-0.470.62-0.29-0.110.550.7-0.29-0.290.4-0.57-0.340.430.480.940.610.51-0.59
-0.420.76-0.340.780.760.710.390.28-0.570.660.040.050.660.920.060.190.55-0.16-0.440.550.590.640.080.64-0.38
-0.391.0-0.660.990.760.65-0.110.62-0.450.59-0.25-0.070.550.67-0.31-0.270.35-0.57-0.330.380.440.90.610.49-0.58
-0.490.65-0.180.660.710.650.210.08-0.520.60.220.410.570.60.030.020.59-0.02-0.710.340.310.560.20.34-0.17
-0.34-0.110.56-0.120.39-0.110.21-0.6-0.320.240.680.460.380.280.620.520.420.31-0.360.30.31-0.31-0.840.070.3
0.240.62-0.990.640.280.620.08-0.60.070.06-0.92-0.77-0.130.37-0.83-0.36-0.27-0.820.29-0.050.120.770.780.25-0.7
0.67-0.45-0.02-0.47-0.57-0.45-0.52-0.320.07-0.96-0.35-0.33-0.93-0.71-0.37-0.3-0.870.050.88-0.91-0.83-0.46-0.02-0.760.53
-0.630.59-0.120.620.660.590.60.240.06-0.960.230.260.930.740.280.220.86-0.14-0.840.910.860.610.140.79-0.54
-0.51-0.250.89-0.290.04-0.250.220.68-0.92-0.350.230.910.45-0.090.860.320.520.72-0.540.270.09-0.49-0.65-0.040.53
-0.56-0.070.73-0.110.05-0.070.410.46-0.77-0.330.260.910.43-0.120.70.180.530.6-0.610.21-0.08-0.3-0.38-0.170.48
-0.740.550.080.550.660.550.570.38-0.13-0.930.930.450.430.690.420.290.820.03-0.820.840.810.440.010.76-0.42
-0.390.67-0.430.70.920.670.60.280.37-0.710.74-0.09-0.120.69-0.050.330.55-0.25-0.50.650.720.660.150.8-0.65
-0.37-0.310.82-0.290.06-0.310.030.62-0.83-0.370.280.860.70.42-0.050.210.630.69-0.430.490.24-0.42-0.680.060.52
-0.2-0.270.34-0.290.19-0.270.020.52-0.36-0.30.220.320.180.290.330.210.120.33-0.260.220.23-0.33-0.530.3-0.13
-0.610.350.210.40.550.350.590.42-0.27-0.870.860.520.530.820.550.630.120.17-0.880.890.680.35-0.140.53-0.14
-0.08-0.570.81-0.57-0.16-0.57-0.020.31-0.820.05-0.140.720.60.03-0.250.690.330.17-0.14-0.03-0.21-0.69-0.55-0.10.69
0.7-0.33-0.21-0.34-0.44-0.33-0.71-0.360.290.88-0.84-0.54-0.61-0.82-0.5-0.43-0.26-0.88-0.14-0.73-0.59-0.310.06-0.50.25
-0.520.380.010.430.550.380.340.3-0.05-0.910.910.270.210.840.650.490.220.89-0.03-0.730.860.44-0.050.75-0.42
-0.440.44-0.150.480.590.440.310.310.12-0.830.860.09-0.080.810.720.240.230.68-0.21-0.590.860.51-0.010.89-0.57
-0.230.9-0.80.940.640.90.56-0.310.77-0.460.61-0.49-0.30.440.66-0.42-0.330.35-0.69-0.310.440.510.710.54-0.71
0.030.61-0.780.610.080.610.2-0.840.78-0.020.14-0.65-0.380.010.15-0.68-0.53-0.14-0.550.06-0.05-0.010.710.2-0.58
-0.370.49-0.280.510.640.490.340.070.25-0.760.79-0.04-0.170.760.80.060.30.53-0.1-0.50.750.890.540.2-0.66
0.21-0.580.7-0.59-0.38-0.58-0.170.3-0.70.53-0.540.530.48-0.42-0.650.52-0.13-0.140.690.25-0.42-0.57-0.71-0.58-0.66
Click cells to compare fundamentals

Bone Biologics Account Relationship Matchups

Bone Biologics fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding12.2K12.1K18.9K47.6K263.1K250.0K
Total Assets30.8K0.06.7M8.5M3.7M2.3M
Net Debt11.3M11.7M(6.7M)(7.5M)(3.0M)(2.9M)
Cash24.1K0.06.7M7.5M3.0M2.0M
Cash And Short Term Investments955.4K24.1K6.7M7.5M3.0M2.1M
Liabilities And Stockholders Equity30.8K13.7M6.7M8.5M3.7M3.5M
Total Current Assets30.8K0.06.7M8.5M3.7M2.3M
Other Current Liab513.7K535.6K1.5M2.5M470.7K447.2K
Total Current Liabilities578.4K13.7M99.9K2.5M831.4K789.8K
Total Stockholder Equity(11.9M)(13.7M)6.6M5.9M2.9M3.1M
Retained Earnings(67.0M)(68.9M)(70.5M)(72.0M)(80.9M)(76.9M)
Total Liab11.9M13.7M99.9K2.5M831.4K789.8K
Short Long Term Debt Total8.2M9M11.3M11.7M13.5M8.3M
Other Current Assets105.2K85.3K6.7K956.9K711.2K746.8K
Accounts Payable42.9K465.4K99.9K888.46360.7K202.9K
Non Current Liabilities Total11.3M12.2M99.9K888.46799.61759.63
Net Invested Capital(547.6K)(2.0M)6.6M5.9M2.9M2.1M
Net Working Capital(547.6K)(13.7M)6.6M5.9M2.9M3.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.